Drug manufacturer Janssen Pharmaceutical Inc. announced in 2000 it would voluntarily stop marketing Propulsid, also known as Cisapride, in the United States. Propulsid was prescribed to people with Gastroesophageal Reflux Disease (GERD) and worked by increasing muscle tone in the esophageal sphincter.
The drug, however, was linked to irregular heartbeats and in some cases resulted in sudden death.
Serious side effects include cardiac arrest in people who had no prior heart diseases, as well as rhythm irregularities. The label for Propulsid was revised several times to inform users and health care professionals about various side effects and risks.